DASON COVID-19 Weekly Treatment Literature Update 8/7/2020

Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week.

*Note: some of the data discussed below is in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

**NIH Guideline Updates**

There were no updates to the NIH COVID-19 treatment guidelines since the last update on 7/30.

**Other Treatment Updates**

There was a nice review published describing drug-drug interactions with medications used for COVID-19 by the University of Liverpool group, who have also published an online COVID-19 Drug Interactions Checker.

An international working group published a living systematic review of drug treatments for COVID-19 in the BMJ. This has an interactive graphic summarizing impact of the various treatments on outcomes such as mortality, time to viral clearance, and adverse events based on data from controlled clinical trials.

NIH announced in a press-release the initiation of the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT3) evaluating remdesivir plus subcutaneous interferon beta-1a for COVID-19 in hospitalized patients. The second iteration of the trial, ACTT2, evaluating remdesivir plus baricitinib for COVID-19, closed to enrollment June 30, but results have not yet been released.

There has been a lot of discussion in the press this week about vaccines. Here is a nice recent review of the various vaccine technologies and vaccines under development for COVID-19.

**Treatment Summary Tables**

The remdesivir summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

The hydroxychloroquine summary table is available at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-hydroxychloroquine-and-chloroquine-covid-19

The tocilizumab summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-tocilizumab-covid-19